Welcome to our dedicated page for Aura Biosciences SEC filings (Ticker: AURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aura Biosciences, Inc. filings document a clinical-stage biotechnology issuer focused on precision therapies for solid tumors and its common stock listed on The Nasdaq Global Market under AURA. Form 8-K disclosures cover operating and financial results, corporate presentations, executive leadership changes, material agreements, and equity financing activity involving common stock and pre-funded warrants.
Proxy materials describe annual meeting proposals, director elections, auditor ratification, voting results, and board governance. The filing record also includes capital-structure disclosure, risk-factor disclosure, and updates tied to Aura’s clinical pipeline, including bel-sar (AU-011) in ocular oncology and bladder cancer indications.
Aura Biosciences, Inc. director Jeremy Bender reported equity awards consisting of restricted stock units and stock options as part of his compensation. He received 30,000 shares of Common Stock through an RSU award, with each unit representing one share. These RSUs vest in three substantially equal annual installments beginning on July 15, 2027, subject to his continued service.
He was also granted 60,000 stock options to purchase Common Stock at an exercise price of $7.03 per share, expiring on July 7, 2036. The option vests in three substantially equal annual installments beginning on July 7, 2027, conditioned on his continued service. After these awards, he holds 30,000 shares of Common Stock and 60,000 stock options directly.
Aura Biosciences, Inc. filed an initial Form 3 for director Jeremy Bender. This filing establishes his status as a reporting person but shows no reportable transactions, no current holdings entries, and no derivative positions, based on the zero counts in the transaction and derivative summaries.
Aura Biosciences expanded its Board of Directors from six to seven members and appointed Jeremy Bender, Ph.D., M.B.A., as a Class II independent director effective July 7, 2026, with a term running through the 2029 annual stockholders’ meeting. He will also serve on the Compensation and Nominating and Corporate Governance Committees.
Under the company’s amended Non-Employee Director Compensation Policy, Dr. Bender receives an initial stock option for 60,000 shares and an initial restricted stock unit award for 30,000 shares, vesting in three equal annual installments. The policy provides a $40,000 annual board retainer for members, higher retainers for committee roles, and larger ongoing annual equity awards, subject to caps of $800,000 for initial grants and $400,000 for annual grants. The press release highlights his biotechnology leadership experience and Aura’s late-stage development of its lead candidate bel-sar for early choroidal melanoma.
Kilroy Conor reported acquisition or exercise transactions in this Form 4 filing.
Aura Biosciences, Inc. reported that company officer Conor Kilroy received a grant of 14,858 shares of Common Stock in the form of restricted stock units (RSUs) at no cash cost. Each RSU represents one share of common stock.
The RSUs vest in two substantially equal annual installments beginning on July 15, 2027, conditioned on Kilroy’s continued service on each vesting date. Following this award, Kilroy directly holds a total of 232,693 shares of Aura Biosciences common stock.
Aura Biosciences is calling a virtual special stockholder meeting on August 5, 2026 to vote on two key proposals affecting its capital structure and equity incentives.
Stockholders are asked to approve a charter amendment increasing authorized common shares from 150,000,000 to 500,000,000. As of June 1, 2026, 103,397,416 shares were outstanding and total share usage, including equity plans and warrants, was 135,371,499 shares, or 90% of the 150,000,000 authorized. The board argues that more authorized shares are needed to support future capital raises, strategic deals and employee equity. The second proposal amends the 2021 Stock Option and Incentive Plan’s evergreen provision so that outstanding pre-funded warrants are counted as if they were common shares when calculating annual share pool increases from 2027 through 2031, modestly expanding future equity capacity for employee grants.
Aura Biosciences is asking shareholders to vote at a virtual Special Meeting on August 5, 2026 to approve two governance items.
First, Proposal No. 1 would amend the charter to increase authorized common shares from 150,000,000 to 500,000,000. Second, Proposal No. 2 would amend the 2021 Stock Option and Incentive Plan to include pre-funded warrants in the plan's annual "evergreen" share-count formula (effective for increases beginning January 1, 2027 through plan expiration in October 2031). The proxy discloses 103,436,416 shares outstanding as of June 12, 2026 and share-usage tables as of June 1, 2026. The board recommends a FOR vote on both proposals.
Aura Biosciences, Inc. reports a proposed sale of 37,500 shares of Common Stock represented by a restricted stock unit award granted under the company's 2021 Stock Option and Incentive Plan. The RSU award is dated 06/02/2025 and the Form 144 filing entry is dated 06/16/2026.
The entry lists the securities to be sold as Common Stock on Nasdaq and identifies the award as subject to vesting requirements under the 2021 plan.
Aura Biosciences, Inc. officer Anthony S. Gibney reported an automatic sale of common stock tied to tax withholding. On June 16, 2026, 12,824 shares were sold at $6.42 per share to cover tax obligations from vesting restricted stock units, leaving him with 265,354 directly held shares. The footnote states these sales were executed automatically and not at his discretion.
Aura Biosciences director Teresa Marie Bitetti received new equity awards as part of her compensation. She was granted 15,000 restricted stock units, each representing one share of common stock, and 30,000 stock options with an exercise price of $6.21 per share.
The RSUs and options each vest in full on the earlier of June 11, 2027 or the next annual meeting of stockholders, subject to her continued service. After the grant, she holds 36,000 shares of common stock directly, plus the newly awarded 30,000 options.
Aura Biosciences director Sapna Srivastava received new equity awards in the form of stock and options. She was granted 15,000 shares of Common Stock through a restricted stock unit (RSU) award and 30,000 stock options with an exercise price of $6.21 per share.
The RSUs and options each vest in full on the earlier of June 11, 2027 or the company’s next annual stockholder meeting, subject to her continued service. After the RSU grant, her direct Common Stock holdings total 38,500 shares, and she holds 30,000 options to buy additional shares.